The last week of this financial year witnessed a lot of bulk deals. I, therefore, would only be discussing selective candidates here at my discretion.
Credit Suisse Singapore was seen picking-up shares worth Rs. 12.5 crores in Arshiya International, a supply chain and logistic company, which has made it to the Ceejay House of Worli from an unknown office building in Marol, Andheri. Seller here was Citigroup.
Buying interest was seen in another company named Gateway Distriparks, which operates in similar space as Arshiya International. Morgan Stanley and Indea Absolute Return Fund were the buyers here, picking shares worth Rs. 37.7 crores and Rs. 8.3 crores each.
ICICI Prudential Mutual Fund bought shares worth Rs. 12.2 crores in Career Point, a tutorial company, from HDFC Mutual Fund. Few interesting things about Career Point: 1) the stock is available at 52-week low and could make for a good investment, 2) expected IPO of Mahesh Tutorials could be seen lifting investor interest, and 3) the company has some really strong backing of institutional investors.
However, ICICI Prudential Mutual Fund was seen selling shares in Shilpa Medicare. The fund house sold shares worth Rs. 7.9 crores to TANO Mauritius India. Shilpa Medicare counts Baring India and Pivotal Securities among its shareholders.
During the week, New York Life Investment Management India Fund bought shares worth Rs. 6 crores in Jabalpur-based Commercial Engineers & Body Builders. Since, they already own 12% outstanding shares in the company, the additional buying of shares indicate confidence among the existing investors.
Asian Satellite Broadcast (a Subhash Chandra company) was seen buying into IVRCL. Asian Satellite Broadcast acquired a total of 13 million shares at an average price of Rs. 60.44 per share, this week.
And lastly, my all-time favorite Supreme Infrastructure is again back in the list since Kitara Capital bought additional shares worth Rs. 2.9 crores at an average price of Rs. 288 in the company.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment